African Health Sciences
Makerere University Medical School
Vol. 21, No. 1, 2021, pp. 1-7
Bioline Code: hs21002
Full paper language: English
Document type: Research Article
Document available free of charge
African Health Sciences, Vol. 21, No. 1, 2021, pp. 1-7
© Copyright 2021 - Ma J et al.
The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies|
Ma, Jian; Zhao, Yanhong; Fan, Huihui & Liu, Jia
Introduction: The efficacy of dapagliflozin for type 1 diabetes remains controversial. We conduct a systematic review and
meta-analysis to explore the treatment efficacy of dapagliflozin versus placebo in patients with type 1 diabetes.
Methods: We have searched PubMed, EMbase, Web of science, EBSCO and Cochrane library databases through May
2019 for randomized controlled trials (RCTs) assessing the effect of dapagliflozin versus placebo for type 1 diabetes. This
meta-analysis is performed using the random-effect model.
Results: Six RCTs are included in the meta-analysis. Overall, compared with control group for type 1 diabetes, dapagliflozin
treatment shows favorable impact on glycated hemoglobin HbA1c ( standard mean difference SMD=-3.93; 95% confidence
interval CI =-4.44 to -3.48; P<0.00001), HbA1c reduction of ≥0.5% (risk ratio RR=1.98; 95% CI=1.65 to 2.39; P<0.00001),
and fasting plasma glucose FPG (SMD=-0.93; 95% CI=-1.77 to -0.10; P=0.03). There is no statistical difference of hypoglycemia
(RR=1.09; 95% CI=0.66 to 1.79; P=0.75) or adverse events (RR=1.07; 95% CI=0.96 to 1.20; P=0.20) between two
groups, but the incidence of ketone-related events is higher than those in control group (RR=0.28; 95% CI=3.96 to 11.52;
Conclusions: Dapagliflozin treatment benefits to reduce HbA1c and FPG for type 1 diabetes.
Dapagliflozin; type 1 diabetes; glycemic control; randomized controlled trials.